Perspective
Why Doctors Should Worry about Preemption
N Engl J Med 2008; 359:1-3July 3, 2008
- Article
Interactive Timeline
Safety Problems Associated with Four Drugs.
A leading drug company may be poised to win a landmark legal victory next fall. If the drug manufacturer, Wyeth, prevails in a case soon to be argued before the U.S. Supreme Court (Wyeth v. Levine),1 drug companies could effectively be immunized against state-level tort litigation if their products that have been approved by the Food and Drug Administration (FDA) are later found to be defective.
A medical-device company won such a victory in April. In Riegel v. Medtronic, 2 the Supreme Court determined that a product-liability lawsuit against Medtronic in a state court was preempted because the device had received FDA approval. Preemption is a legal doctrine based on the supremacy clause of the U.S. Constitution, which states that when federal and state laws are at odds, federal law takes precedence. Its application to state tort litigation is a radical extension of its original meaning.
Medtronic won its case because the 1976 law that grants the FDA authority to regulate medical devices contains a clause asserting that state requirements with regard to medical devices are preempted by federal requirements. Although the preemption clause is silent on common-law tort actions, the Supreme Court (with Justice Antonin Scalia writing for the Court) interpreted the preemption clause broadly to include such actions.
Unlike the law governing medical devices, the Food, Drug, and Cosmetic Act, which provides the statutory framework for the regulation of drugs by the FDA, contains no such preemption clause. Thus, in Wyeth v. Levine — which concerns a patient who lost her arm after an injection of Wyeth's antiemetic drug Phenergan — the Court will decide whether preemption of state tort litigation is implied by the law, even though it is not explicitly stated.
Previous administrations and the FDA considered tort litigation to be an important part of an overall regulatory framework for drugs and devices; product-liability litigation by consumers was believed to complement the FDA's regulatory actions and enhance patient safety. Margaret Jane Porter, former chief counsel of the FDA, wrote, “FDA product approval and state tort liability usually operate independently, each providing a significant, yet distinct, layer of consumer protection.”3 Persons who are harmed have the right to seek legal redress. Preemption would erase that right.
But in the past few years, the government's views have shifted, and the FDA has reversed its position, now claiming that common-law tort actions are preempted. The FDA argues that tort liability stifles innovation in product development and delays the approval process, and that lay juries are incapable of making determinations about product safety. It has been argued, however, that Congress, not unelected appointees of a federal agency, has the power to decide whether preemption should apply.
Drug and device companies have chosen an inauspicious moment to attack the right of patients to seek redress. A series of pivotal reports on patient safety from the Institute of Medicine, as well as numerous articles in scholarly journals, has put the issue of patient safety in the national spotlight. Although frivolous lawsuits should not be condoned, product-liability litigation has unquestionably helped to remove unsafe products from the market and to prevent others from entering it. Through the process of legal discovery, litigation may also uncover information about drug toxicity that would otherwise not be known. Preemption will thus result in drugs and devices that are less safe and will thereby undermine a national effort to improve patient safety.
Owing in part to a lack of resources, approval of a new drug by the FDA is not a guarantee of its safety (see timeline
Four Drugs with Safety Problems Discovered after FDA Approval.).4 As the Institute of Medicine has reported, FDA approval is usually based on short-term efficacy studies, not long-term safety studies.5 Despite the diligent attention of the FDA, serious safety issues often come to light only after a drug has entered the market. The FDA, which — unlike most other federal agencies — has no subpoena power, knows only what manufacturers reveal.Why should doctors be concerned about preemption? In stripping patients of their right to seek redress through due process of law, preemption of common-law tort actions is not only unjust but will also result in the reduced safety of drugs and medical devices for the American people. Preemption will undermine the confidence that doctors and patients have in the safety of drugs and devices. If injured patients are unable to seek legal redress from manufacturers of defective products, they may instead turn elsewhere.
In May, a Congressional hearing on preemption was held by Representative Henry Waxman (D-CA) and the House Committee on Oversight and Government Reform. As we stated in our testimony to the committee, to ensure the safety of medical devices, we urge Congress to act quickly to reverse the Riegel decision. Congressman Waxman and Congressman Frank Pallone, Jr. (D-NJ), are poised to introduce legislation that would unambiguously eliminate the possibility of preemption of common-law tort actions for medical devices. And if the Supreme Court rules for preemption in Wyeth v. Levine, which we hope it will not, Congress should consider similar legislation for drugs. Such legislation is in the best interest of the health and safety of the American public.
An interactive timeline is available with the full text of this article at www.nejm.org.
Source Information
Dr. Curfman is the executive editor, Dr. Morrissey the managing editor, and Dr. Drazen the editor-in-chief of the Journal.
- References
References
1
Wyeth v. Levine, cert. granted, 128 S. Ct. 1118 (2008).
2
Riegel v. Medtronic, 128 S. Ct. 999 (2008).
3
Porter MJ . The Lohr decision: FDA perspective and position. Food Drug Law J 1997;52:7-11
Web of Science | Medline4
Kessler DA, Vladeck DC. A critical examination of the FDA's efforts to preempt failure-to-warn claims. Georgetown Law J 2008;96(2). (Accessed June 13, 2008, at http://lsr.nellco.org/georgetown/ois/papers/2/.)
5
Baciu A, Stratton K, Burke SP, eds. The future of drug safety: promoting and protecting the health of the public. Washington, DC: National Academies Press, 2007.
- Citing Articles (13)
Citing Articles
1
Tse-Ching Chen, Yi-Yin Jan, Ta-Sen Yeh. (2012) K-ras Mutation is Strongly Associated with Perineural Invasion and Represents an Independent Prognostic Factor of Intrahepatic Cholangiocarcinoma after Hepatectomy. Annals of Surgical Oncology
CrossRef2
E. Bahlmann, C. A. Nienaber, D. Cramariuc, C. Gohlke-Baerwolf, S. Ray, R. B. Devereux, K. Wachtell, K. H. Kuck, E. Davidsen, E. Gerdts. (2011) Aortic root geometry in aortic stenosis patients (a SEAS substudy). European Journal of Echocardiography 12:8, 585-590
CrossRef3
R. Meredith Elkins, R. Kathryn McHugh, Lauren C. Santucci, David H. Barlow. (2011) Improving the Transportability of CBT for Internalizing Disorders in Children. Clinical Child and Family Psychology Review 14:2, 161-173
CrossRef4
Simran Maggo. (2011) Research Highlights. Pharmacogenomics 12:6, 773-778
CrossRef5
Simran D.S. Maggo, Martin A. Kennedy, David W.J. Clark. (2011) Clinical Implications of Pharmacogenetic Variation on the Effects of Statins. Drug Safety 34:1, 1-19
CrossRef6
A. I. Adler, S. Erqou, T. A. S. Lima, A. H. N. Robinson. (2010) Association between glycated haemoglobin and the risk of lower extremity amputation in patients with diabetes mellitus—review and meta-analysis. Diabetologia 53:5, 840-849
CrossRef7
M. Shawn McFarland, Tara N. Knight, Andrea Brown, Jeremy Thomas. (2010) The Continuation of Oral Medications with the Initiation of Insulin Therapy in Type 2 Diabetes: A Review of the Evidence. Southern Medical Journal 103:1, 58-65
CrossRef8
Robert G Turcott, Euan A Ashley. (2009) The Medical Device Safety Act of 2009: Clarifying Preemption. American Journal of Therapeutics 16:6, 471-474
CrossRef9
Roberta Ara, Rachid Rafia, Sue E Ward, Anthony S Wierzbicki, Tim M Reynolds, Angie Rees, Abdullah Pandor. (2009) Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective. Expert Review of Pharmacoeconomics & Outcomes Research 9:5, 423-433
CrossRef10
Annas, George J., . (2009) Good Law from Tragic Facts — Congress, the FDA, and Preemption. New England Journal of Medicine 361:12, 1206-1211
Full Text11
Carmel Shachar, Pooja Nair. (2009) Recent Developments in Health Law. The Journal of Law, Medicine & Ethics 37:3, 523-530
CrossRef12
A. D. Johnson, M. Kavousi, A. V. Smith, M.-H. Chen, A. Dehghan, T. Aspelund, J.-P. Lin, C. M. van Duijn, T. B. Harris, L. A. Cupples, A. G. Uitterlinden, L. Launer, A. Hofman, F. Rivadeneira, B. Stricker, Q. Yang, C. J. O'Donnell, V. Gudnason, J. C. Witteman. (2009) Genome-wide association meta-analysis for total serum bilirubin levels. Human Molecular Genetics 18:14, 2700-2710
CrossRef13
Andrew Lee Foret, Andrew P. Bozeman, Waldo E. Floyd. (2009) Necrosis Caused by Intra-arterial Injection of Promethazine: Case Report. The Journal of Hand Surgery 34:5, 919-923
CrossRef
